Description

AMANTREL ER 129 MG

Indications

Amantrel ER 129 mg is primarily indicated for the treatment of Parkinson’s disease and certain types of viral infections, particularly those caused by the influenza virus. It may also be used as an adjunct therapy in the management of specific movement disorders. The extended-release formulation allows for once-daily dosing, which can enhance patient compliance and convenience.

Mechanism of Action

Amantrel, the active ingredient in Amantrel ER, is an antiviral and antiparkinsonian agent. Its mechanism of action is multifaceted. In the context of Parkinson’s disease, amantadine is believed to increase dopamine release and inhibit its reuptake, thereby enhancing dopaminergic transmission in the brain. Additionally, it may exert effects on the NMDA (N-methyl-D-aspartate) receptor, which is involved in glutamate neurotransmission, potentially reducing excitotoxicity and improving motor function.

As an antiviral, amantadine interferes with the uncoating of the influenza virus, preventing it from releasing its RNA into the host cell, thereby inhibiting viral replication. This dual action makes it a valuable therapeutic option in both neurological and infectious diseases.

Pharmacological Properties

Amantrel ER is characterized by its extended-release formulation, which allows for a gradual release of the active ingredient over a 24-hour period. This property helps maintain stable plasma levels of the drug, reducing the frequency of dosing and minimizing side effects associated with peak concentrations. Amantadine is well-absorbed from the gastrointestinal tract, with bioavailability ranging from 90-100%. It is primarily excreted unchanged in the urine, necessitating dose adjustments in patients with renal impairment.

Contraindications

Amantrel ER is contraindicated in patients with a known hypersensitivity to amantadine or any of the excipients in the formulation. It should not be used in individuals with a history of seizures or those with severe renal impairment unless closely monitored by a healthcare provider. Caution is advised in patients with a history of heart disease, as amantadine may cause cardiovascular effects.

Side Effects

Common side effects associated with Amantrel ER include dizziness, insomnia, nausea, and dry mouth. Patients may also experience gastrointestinal disturbances such as constipation or diarrhea. In some cases, more serious side effects may occur, including hallucinations, confusion, and worsening of existing psychiatric conditions. It is essential for patients to report any unusual or severe side effects to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of Amantrel ER for adults with Parkinson’s disease is typically 129 mg once daily. Depending on the patient’s response and tolerance, the dose may be adjusted by the healthcare provider. It is important to take the medication at the same time each day to maintain consistent drug levels in the body. Patients should swallow the tablet whole and not crush or chew it, as this may alter the release properties of the medication.

Interactions

Amantrel ER may interact with several medications, which can affect its efficacy or increase the risk of adverse effects. Co-administration with other central nervous system (CNS) depressants, such as alcohol, benzodiazepines, or opioids, may enhance sedative effects. Additionally, medications that affect renal function may alter the clearance of amantadine, necessitating dose adjustments. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before starting Amantrel ER, patients should undergo a thorough medical evaluation, particularly focusing on renal function, cardiovascular health, and psychiatric history. Regular monitoring may be necessary for patients with a history of seizures or those taking other medications that may lower the seizure threshold. Caution is also advised in elderly patients, as they may be more susceptible to side effects. Patients should be educated about the potential for dizziness or drowsiness and advised to avoid activities that require alertness until they know how the medication affects them.

Clinical Studies

Clinical studies have demonstrated the efficacy of amantadine in improving motor symptoms in patients with Parkinson’s disease. A randomized controlled trial showed that patients receiving amantadine experienced significant improvements in motor function compared to those receiving a placebo. Additionally, studies have highlighted its role in reducing the severity of dyskinesias associated with long-term dopaminergic therapy. The antiviral properties of amantadine have also been well-documented, particularly in the context of influenza A virus infections, where it has been shown to reduce the duration and severity of symptoms when administered early in the course of illness.

Conclusion

Amantrel ER 129 mg is a valuable therapeutic option for patients with Parkinson’s disease and certain viral infections. Its unique pharmacological properties, including extended-release formulation, make it a convenient choice for long-term management. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should work closely with their healthcare providers to optimize their treatment regimen and ensure the best possible outcomes.